Home    Back

Over the counter dha/epa dietary supplementation    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
301Macular dystrophy1

301. Macular dystrophy    [ 41 clinical trials,   47 drugs,   (DrugBank: 12 drugs),   12 drug target genes,   66 drug target pathways]
Searched query = "Macular dystrophy", "Best disease", "Stargardt disease", "Cone dystrophy", "Cone rod dystrophy", "X-linked juvenile retinoschisis", "Central areolar choroidal dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 41 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00420602
(ClinicalTrials.gov)		September 21, 200710/1/2007DHA Supplementation in Patients With STGD3Clinical Interventions Against Stargardt Macular Dystrophy: DHA Supplementation in Patients With STGD3Dominantly Inherited Stargardt's Disease (STGD3)Dietary Supplement: Over the counter DHA/EPA dietary supplementationUniversity of UtahNULLCompleted18 Years105 YearsAll11N/AUnited States